🇰🇷South Korea·Policy·14 Oct 2026·via Koreajoongangdaily Joins News
Hanmi’s Eppe obesity drug to undercut Mounjaro and Wegovy in Korea
Hanmi Pharmaceutical plans to launch Eppe, Korea’s first homegrown GLP-1 obesity drug, with a first-month wholesale price of about 130,000 won, below Mounjaro and Wegovy.
Share this article
Original reporting by Koreajoongangdaily Joins NewsWe don't republish, read the full story →
Related reading
6 stories
🇰🇷·Startups
Intero Biosystems wants drugmakers to test on mini human intestines, not animals
🇰🇷·AI News
Mosqitter is turning its mosquito traps into an AI-powered surveillance network
🇹🇼·Policy
IBM and Siemens Collaborate on Research to Advance Nanostack Architecture
🇨🇳·Policy
China approves Alibaba AI models for use in iPhone Duo and other Apple handsets
🇰🇷·AI News
Hyundai Chief Pledges Investment Beyond Cars Into India's Infrastructure, Energy
🇹🇼·Policy